Bill Oxford/iStock via Getty Images Axonics ( NASDAQ: AXNX ) Thursday said that it has received regulatory approval from the Therapeutic Goods Administration for marketing the Axonics R20 rechargeable sacral neuromodulation system in Australia to treat adults with overactive bladder and fecal incontinence. The R20 neurostimulator is labeled for.
Back to Health Page
